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Screening for Cognitive Impairment in Older Adults
US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force
Summary of Recommendation
Importance
According to the American Psychiatric Association’s Diagnostic and
Statistical Manual of Mental Disorders (Fifth Edition) (DSM-5), demen-
tia (also known as major neurocognitive disorder) is defined by a sig-
nificant decline in 1 or more cognitive domains that interferes with a
person’s independence in daily activities. The 6 cognitive domains
identified in the DSM-5 are complex attention, executive function,
learning and memory, language, perceptual motor function, and so-
cial cognition.1 Dementia affects an estimated 2.4 to 5.5 million per-
sons in the United States, and its prevalence increases with age. De-
mentia affects an estimated 3.2% of persons aged 65 to 74 years, 9.9%
of those aged 75 to 84 years, and 29.3% of those 85 years or older.2
Mild cognitive impairment (MCI) differs from dementia in that
the impairment is not severe enough to interfere with independent
daily functioning. Some persons with MCI may progress to
dementia, while some do not. One systematic review found that
32% of persons with MCI develop dementia over 5 years.3 How-
ever, studies have also shown that between 10% and 40% of per-
sons with MCI may return to normal cognition over approximately
4 to 5 years.4-6 The prevalence of MCI is difficult to estimate, in part
because of differing diagnostic criteria, leading to a wide range
of prevalence estimates (3%-42%) in adults 65 years or older.7,8
In this recommendation statement, “cognitive impairment” refers
to both dementia and MCI.
USPSTF Assessment of Magnitude of Net Benefit
The US Preventive Services Task Force (USPSTF) concludes that the
evidence is lacking, and the balance of benefits and harms of screen-
ing for cognitive impairment cannot be determined (Figure and
Table).
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits
and harms of screening for cognitive impairment in older adults.
I
See the Figure for a more detailed summary of the recommendation for clinicians. See the Practice Considerations section for suggestions for practice
regarding the I statement.
IMPORTANCE Dementia (also known as major neurocognitive disorder) is defined by a
significant decline in 1 or more cognitive domains that interferes with a person’s
independence in daily activities. Dementia affects an estimated 2.4 to 5.5 million individuals
in the United States, and its prevalence increases with age.
OBJECTIVE To update its 2014 recommendation, the US Preventive Services Task Force
(USPSTF) commissioned a review of the evidence on screening for cognitive impairment,
including mild cognitive impairment and mild to moderate dementia, in community-dwelling
adults, including those 65 years or older residing in independent living facilities.
POPULATION This recommendation applies to community-dwelling older adults 65 years or
older, without recognized signs or symptoms of cognitive impairment.
EVIDENCE ASSESSMENT The USPSTF concludes that the evidence is lacking, and the balance
of benefits and harms of screening for cognitive impairment cannot be determined.
RECOMMENDATION The USPSTF concludes that the current evidence is insufficient to assess
the balance of benefits and harms of screening for cognitive impairment in older adults.
(I statement)
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Practice Considerations
Patient Population Under Consideration
This recommendation applies to community-dwelling older adults
65 years or older, without recognized signs or symptoms of cogni-
tive impairment. Early detection and diagnosis of dementia through
the assessment of signs and symptoms recognized by the patient,
family, or clinician, which may be subtle, are not considered screen-
ing and are therefore not the focus of this recommendation.
Assessment of Risk
Increasing age is the strongest known risk factor for cognitive
impairment.9 The ε4 allele of the apolipoprotein E (apoE) gene is a
reported risk factor for Alzheimer disease in white and Asian
populations.10 Other risk factors include cardiovascular risk factors
(eg, diabetes, hypertension, or hypercholesterolemia), depression,
physical frailty, low education level, and low social support
level.10-13 Several dietary and lifestyle factors have been reported
as associated with decreased risk of cognitive impairment. These
include adequate folic acid intake, low saturated fat intake, higher
longer-chain omega-3 fatty acid intake, high fruit and vegetable
intake, the Mediterranean diet, moderate alcohol intake (1 to 6
drinks per week vs abstention), higher educational attainment,
cognitive engagement, social engagement, and higher physical
activity levels.10,11,14,15
Screening Tests
Many different brief screening tests for cognitive impairment are
available. Screening tests generally include asking patients to per-
form a series of tasks that assess 1 or more domains of cognitive
function. These tests are not intended to diagnose MCI or demen-
tia. A positive screening test result should lead to additional testing
that can include blood tests, radiology examinations, and a medical
and neuropsychologic evaluation to confirm the diagnosis of
dementia and determine its subtype.
Figure. Clinician Summary: Screening for Cognitive Impairment in Older Adults
What does the USPSTF
recommend?
For asymptomatic, community-dwelling adults age 65 years and older: I statement
To whom does this
recommendation apply?
What’s new?
How to implement this
recommendation?
The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize
decision-making to the specific patient or situation.
Community-dwelling adults age 65 years and older, without recognized signs or symptoms of cognitive impairment.
It does not apply to persons who are hospitalized or living in institutions such as nursing homes.
This recommendation is consistent with the 2014 USPSTF statement.
There is insufficient evidence to recommend for or against screening for cognitive impairment. Clinicians should remain alert
to early signs or symptoms of cognitive impairment (eg, problems with memory or language) and evaluate as appropriate.
Where to read the full
recommendation
statement?
Visit the USPSTF website to read the full recommendation statement. This includes more details on the rationale of the
recommendation, including benefits and harms; supporting evidence; and recommendations of others.
The USPSTF found that the evidence is insufficient to assess the balance of benefits and harms of screening for cognitive
impairment in older adults. More research is needed.
January 2020
USPSTF indicates US Preventive Services Task Force.
Table. Summary of USPSTF Rationalea
Rationale Assessment
Detection • Adequate evidence that some screening tools have relatively high sensitivity and specificity for the detection of dementia
• When the prevalence of dementia is high (eg, in persons ≥85 y), positive predictive values can be greater than 50%. However,
because of lower prevalence, the positive predictive value can be closer to 20% in unselected populations of adults aged 65 to 74 y
• Sensitivity and specificity of screening tools is generally lower for the detection of MCI than it is for dementia
Benefits of early detection
and intervention and
treatment
• Inadequate direct evidence on the benefits of screening for cognitive impairment
• Adequate evidence that AChEIs and memantine have a small effect on measures of cognitive function in the short term for patients
with mild to moderate dementia, but it is uncertain if the effects reported in studies are clinically meaningful or sustained
over the long term
• Inadequate evidence on the benefits of other medications or supplements (eg, statins, antihypertensives, or vitamins) and
nonpharmacologic interventions targeted to patients
• Adequate evidence that interventions to support caregivers have a small effect on measures of caregiver burden and depression,
but the clinical importance of these effects are uncertain, and the generalizability of these findings to persons with previously
unrecognized dementia, detected by screening, is not known
• Inadequate evidence on the benefits of interventions targeting decision-making or planning by patients, caregivers, or clinicians
Harms of early detection
and intervention and
treatment
• Inadequate direct evidence on the harms of screening for cognitive impairment
• Inadequate evidence on the harms of nonpharmacologic interventions targeted at the patient, caregiver, or both
• Adequate evidence that AChEIs are associated with adverse effects, which overall are small but occasionally serious, including
syncope or falls
USPSTF assessment • Evidence on screening for cognitive impairment is lacking and the balance of benefits and harms cannot be determined
Abbreviations: AChEI, acetylcholinesterase inhibitor; MCI, mild cognitive
impairment; USPSTF, US Preventive Services Task Force.
a See the eFigure in the Supplement for explanation of USPSTF grades and
levels of evidence.
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The most well-studied screening instrument is the Mini-
Mental State Examination (MMSE). Other screening instruments
include the clock drawing test (CDT), Memory Impairment Screen
(MIS)/MIS by Telephone (MIS-T), Mental Status Questionnaire
(MSQ), Mini-Cog verbal fluency, 8-Item Informant Interview
(AD8), Functional Activities Questionnaire (FAQ), 7-Minute
Screen (7MS), Abbreviated Mental Test (AMT), Montreal Cogni-
tive Assessment (MoCA), St. Louis University Mental Status
Examination (SLUMS), Telephone Instrument for Cognitive
Status (TICS), and Informant Questionnaire on Cognitive Decline
in the Elderly (IQCODE). For more information on all screen-
ing instruments reviewed by the USPSTF, see the full evi-
dence report.16,17
Treatment and Interventions
Treatment of cognitive impairment may focus on one or more signs
and symptoms, including cognition, quality of life, mood, and be-
havioral impairments.
Several pharmacologic and nonpharmacologic interventions
aim to slow, prevent, or reverse cognitive impairment; stabilize
or improve functional performance; improve caregiver burden
and depression; or improve patient, caregiver, and clinician
decision-making. Pharmacologic treatments approved by the US
Food and Drug Administration for Alzheimer disease include ace-
tylcholinesterase inhibitors (AChEIs) and memantine. Nonphar-
macologic interventions include cognitive training, cognitive
rehabilitation, cognitive stimulation interventions, exercise, peer
support, psychoeducation, and care management.
Suggestions for Practice Regarding the I Statement
Potential Preventable Burden
Dementia affects an estimated 2.4 to 5.5 million persons in the United
States, and its prevalence increases with age. Dementia affects an
estimated 9.9% of persons aged 75 to 84 years and 29.3% of those
85 years or older.2 Subjective memory issues are common in adults,
with studies showing that approximately 50%18 to 75%19 of adults
have at least minor concerns about their memory.
Although there is insufficient evidence to recommend for
or against screening for cognitive impairment, there may be
important reasons to identify cognitive impairment early. Burdens
of cognitive impairment include direct effects on the patient
(eg, loss of function and relationships, financial misjudgments, and
nonadherence with recommended therapies), direct effects on
caregivers (eg, burden and depression), and effects on society
(eg, costs of care). Early detection of cognitive impairment can
allow for identification and treatment of reversible causes, may
help clinicians anticipate problems patients may have in under-
standing and adhering to medical treatment plans, and may also
be useful by providing a basis for advance planning on the part of
patients and families. Clinicians should remain alert to early signs
or symptoms of cognitive impairment (eg, problems with memory
or language) and evaluate the individual as appropriate. However,
none of the potential benefits of screening have been clearly dem-
onstrated in clinical trials.
Potential Harms
Evidence about the harms of screening is limited. One potential harm
is labeling a person with an illness that is typically progressive and
for which treatment appears to have limited effectiveness. Some
studies have shown higher stress, greater depression, and lower qual-
ity of life in persons aware of a diagnosis of cognitive impairment,20
while others have found no such association.21,22 Evidence about the
effects of false-positive results is limited. AChEIs are associated with
harms, some of which are serious, including central nervous sys-
tem disturbances, bradycardia, and falls. Evidence about the harms
of nonpharmacologic interventions is limited, but these harms are
assumed to be small.
Current Practice
Most commonly, evaluation for or diagnosis of cognitive impair-
ment occurs as a result of patient- or caregiver-reported concerns
or symptoms, or clinician’s suspicion. As many as 29% to 76%
of patients with dementia are unrecognized in the primary care
setting.23-25 In 2011, Medicare added detection of cognitive impair-
ment to its annual wellness visit. The Centers for Medicare & Med-
icaid Services recommend assessing a patient’s cognitive function
by direct observation; considering information and concerns re-
ported by the patient, family members, friends, caregivers, and oth-
ers; and, if deemed appropriate, using a brief validated, structured
cognitive assessment tool.26
Additional Tools and Resources
The National Institute on Aging has useful information on the defi-
nition, detection, and management of cognitive impairment for pa-
tients and clinicians, including links to some screening instru-
ments, on its website.27
Other Related USPSTF Recommendations
The USPSTF has recommendations related to several risk factors
for cognitive impairment, including pharmacotherapy and coun-
seling for tobacco cessation28; screening and counseling to
reduce unhealthy alcohol use29; counseling to promote healthful
diet and physical activity30,31; statins to reduce cardiovascular dis-
ease risk32; and screening for hypertension,33 abnormal blood
glucose levels,34 and depression.35
Update of Previous USPSTF Recommendation
This recommendation updates the 2014 USPSTF recommenda-
tion on screening for cognitive impairment in older adults. In
2014, the USPSTF concluded that the evidence was insufficient to
assess the balance of benefits and harms of screening for cogni-
tive impairment.36 For the current recommendation, the USPSTF
again concludes that the evidence is insufficient to assess the bal-
ance of benefits and harms of screening for cognitive impairment
in older adults.
Supporting Evidence
Scope of Review
To update its 2014 recommendation, the USPSTF commissioned a
systematic review16,17 on the benefits and harms of screening for
cognitive impairment, including MCI and mild to moderate demen-
tia, in community-dwelling adults, including those 65 years or older
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residing in independent living facilities. The systematic review
included evidence on the accuracy of screening tests to detect cog-
nitive impairment and the benefits and harms of treatments and
interventions for older adults with cognitive impairment and their
caregivers. The review focused on older adults with MCI or mild to
moderate dementia, as these are the patients most likely to be
identified by screening.
Accuracy of Screening Tests
The USPSTF found 59 studies that evaluated 49 screening instru-
ments to detect cognitive impairment. Among the studies,
the prevalence of dementia ranged from 1% to 47% and the
prevalence of MCI ranged from 10% to 52%. The mean age of par-
ticipants ranged from 68 to 95 years. Education level of partici-
pants, which was reported in 22 studies, ranged from a mean of
5 to 16 years of education. Most of the instruments evaluated
were very brief (evaluation time 5 minutes) or brief (evaluation
time 10 minutes).16,17
Screening instruments evaluated in more than 1 study
included the MMSE, CDT, MIS/MIS-T, MSQ, Mini-Cog verbal flu-
ency, AD8, FAQ, 7MS, AMT, Lawton Instrumental Activities of
Daily Living Scale, MoCA, SLUMS, TICS, and IQCODE. The MMSE
was the most evaluated instrument (30 studies). The MMSE is
an 11-item instrument with a maximum score of 30 points. In a
pooled analysis of 14 studies using cutoffs of 23 or less or 24 or
less (score considered a positive screening result) (n = 11 972), the
MMSE had a sensitivity of 0.89 (95% CI, 0.85 to 0.92) and a
specificity of 0.90 (95% CI, 0.86 to 0.93) to detect dementia.
The other instruments were studied in fewer studies (2 to 9 stud-
ies), and cutoffs for screening instruments often varied across
studies. Sensitivity and specificity of these instruments to detect
dementia varied widely in these studies, from 0.43 to 1.0 and
0.54 to 1.0, respectively. Across all instruments, test accuracy
(ie, sensitivity and specificity) was generally higher to detect
dementia compared with MCI.16,17
Benefits of Early Detection and Treatment
The USPSTF found 1 trial, IU-CHOICE37 (n = 4005), that examined
the effect of screening for cognitive impairment on health-related
quality of life (HRQOL), health care utilization, and measures of
advance care planning. This trial found no differences in HRQOL
at 1, 6, or 12 months and no differences in health care utilization or
measures of advance care planning at 12 months in screening
compared with control groups. Limitations of this trial include
that 38% of persons assessed for eligibility refused to participate,
and 66% of participants who screened positive refused diagnos-
tic assessment and follow-up. Additionally, the trial was missing
42% of HRQOL outcomes data at 12 months.
The USPSTF found 48 trials (n = 22 431) that evaluated the
effects of AChEIs (donepezil [18 studies; n = 6209], galantamine
[10 studies; n = 7464], rivastigmine [8 studies; n = 4569],
and memantine [12 studies; n = 4189]) on global cognitive func-
tion. Many of these trials reported differences in scores on the
Alzheimer Disease Assessment Scale–Cognitive Subscale (ADAS-
Cog-11) or the MMSE. AChEIs and memantine improved measures
of global cognitive function in the short term, but the magnitude
of change was small. In pooled analyses, the differences in changes
between patients taking AChEIs or memantine compared
with patients taking placebo ranged from approximately 1 to 2.5
points on the ADAS-Cog-11 (scale range, 0-70) and 0.5 to 1 points
on the MMSE (scale range, 0-30) over 3 months to 3 years of
follow-up.16,17 Changes of this magnitude would generally not be
considered clinically important.38 AChEIs and memantine
increased the likelihood of improving or maintaining patients’
global function, typically as assessed by the Clinician’s Interview-
Based Impression of Change Plus Informant Input (CIBIC+), by 15%
(for memantine) to 50% (for rivastigmine) in the short term; how-
ever, change at longer-term follow-up was not reported.16,17
Most of the evidence on the effectiveness of AChEIs and
memantine comes from trials involving persons with dementia, par-
ticularly those with moderate as opposed to mild dementia, and most
commonly Alzheimer disease. Four trials (n = 1919) tested donep-
ezil or memantine in persons with MCI. These trials showed no
improvement in global cognitive function.16,17
Twenty-nine trials (n = 6489) evaluated other medications or
supplements, including antihypertensives, statins, nonsteroidal
anti-inflammatory drugs, gonadal steroids, and dietary supple-
ments and vitamins (multivitamins, B vitamins, vitamin E, and
omega-3 fatty acids). None of the trials found any improvement in
global cognition or physical function in persons with mild to moder-
ate dementia or MCI.16,17
Sixty-one trials (n = 7847) evaluated nonpharmacologic
patient-level interventions, including cognitive-focused, exercise,
multicomponent, and other interventions. In general, these trials
were small and of limited duration. This body of evidence repre-
sented persons with dementia and MCI, with a mean age of 75
years. Among all interventions, there was no clear improvement
in global or domain-specific measures of cognitive function com-
pared with controls at 3 months to 2 years of follow-up.16,17
Fifty-eight trials (n = 9139) evaluated psychoeducation inter-
ventions targeting the caregiver or caregiver-patient dyad. Most
trials targeted patients with dementia, and the average MMSE
score in studies that reported it was 16.2, consistent with moderate
dementia. The interventions were highly variable, with most
including training in problem solving, communications, and stress
management, in addition to providing information about dementia
and community resources. Overall, there was a small improvement
in caregiver burden and depression measures, primarily in persons
caring for patients with moderate dementia. For example, a pooled
analysis of 9 trials (n = 1089) that reported change in the Zarit-22
(a 22-item scale of caregiver burden, with a score ranging from 0 to
88) found an average 2.5-point improvement (mean difference,
–2.5 [95% CI, –3.9 to –1.0]), and a pooled analysis of 20 trials
(n = 2603) that reported change in the Center for Epidemiologic
Studies Depression Scale (CESD) (a 20-item scale of depressive
symptoms, with a score ranging from 0 to 60) found a mean 2.67-
point improvement (mean difference, –2.67 [95% CI, –3.45 to
–1.48]) in the intervention groups.16,17
Seventeen trials (n = 3039) evaluated care or case manage-
ment interventions. All interventions were intended for patients
with dementia. Of the 12 trials that reported caregiver burden out-
comes, 5 found a statistically significant improvement in scores.
A pooled analysis of 8 trials (n = 1215) found a standardized pooled
effect of –0.54 (95% CI, –0.85 to –0.22), translating to a between-
group difference of approximately 3.5 to 4 points on the Zarit-22.
Seven trials reported caregiver depression outcomes. A pooled
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analysis of 4 of these trials (n = 668) showed no improvement in
caregiver depression measures.16,17
Two trials reported the effects of interventions on planning
or decision-making outcomes. One trial (n = 111)39 reported the
effects of a psychoeducational intervention on caregivers’ plan-
ning or decision-making related to caring for a relative with
dementia. Three months after the intervention, caregivers in both
the intervention and usual care groups reported significantly bet-
ter planning for future needs, and there was no difference
between the intervention and usual care groups. A second trial
(the Maximizing Independence at Home [MIND] Care Coordina-
tion Trial) (n = 303)40 assessed whether a care coordination inter-
vention reduced unmet care needs related to dementia com-
pared with usual care. Evaluators assessed 19 common care needs
for participants (71 items) and caregivers (15 items) as being
either “fully met” or “unmet.” After 18 months, there was no dif-
ference in reduction of total percentage of unmet needs in the
intervention group vs usual care.
Overall, the body of evidence on the potential benefits of
screening for cognitive impairment is limited by several factors.
These include the short duration of most trials (often 6 months
for pharmacologic agents and 1 year for nonpharmacologic inter-
ventions), as well as the heterogeneous nature of interventions and
inconsistency in the outcomes reported, which make cross-study
comparisons difficult. As noted, for interventions for which studies
reported an improvement in measures, the average effect sizes
were small and of uncertain clinical importance. In addition, no
interventions specifically targeted a screen-detected population.
Most of the evidence suggesting improvement is applicable to per-
sons with moderate dementia; thus, its applicability to a screen-
detected population is uncertain.
Harms of Screening and Treatment
The USPSTF found 1 trial (IU-CHOICE)37 that addressed the potential
harms of screening for cognitive impairment. This trial and its limita-
tions are described above. The trial found no differences in depres-
sion or anxiety (as measured by PHQ-9 and GAD-7) in participants ran-
domized to screening vs control groups at 1, 6, or 12 months.
Forty-eight randomized clinical trials (n = 22 431) and 3 obser-
vational studies (n = 190 076) reported on the harms of treatment
with AChEIs and memantine.16,17 Adverse effects of medications
were common. Adverse events were significantly higher in patients
receiving AChEIs, and more patients receiving AChEIs withdrew
from studies or discontinued their medication compared with
patients receiving placebo. Memantine was better tolerated,
with no increase in adverse events or withdrawal rates compared
with placebo. Overall, there was no increase in serious adverse
events in patients taking AChEIs. However, some individual studies
reported increased rates of serious adverse events, such as brady-
cardia, syncope, falls, and need for pacemaker placement among
patients taking AChEIs.
Twenty-one of the trials (n = 5688) that evaluated other medi-
cations or supplements reported on harms. Harms were not clearly
significantly increased in intervention groups compared with con-
trol groups.16,17
For nonpharmacologic patient-level interventions, few stud-
ies reported on harms. Little harm was evident in the 12 studies
(n = 2370) that reported it.16,17
Response to Public Comment
A draft version of this recommendation statement was posted for
public comment on the USPSTF website from September 10, 2019,
to October 7, 2019. Several comments agreed that the evidence on
screening for cognitive impairment is insufficient. Several com-
ments expressed that readers might misinterpret the I statement
as a recommendation against screening, or interpreted the
I statement as a recommendation against screening. In response,
the USPSTF wants to clarify that its I statement is a conclusion that
the evidence is insufficient to assess the balance of benefits and
harms of screening for cognitive impairment and is neither a rec-
ommendation for nor against screening. Several comments dis-
agreed with the I statement and felt that the USPSTF should rec-
ommend screening for cognitive impairment based on the potential
benefits mentioned in the Practice Considerations section. In re-
sponse, the USPSTF clarified that while there may be important rea-
sons to identify cognitive impairment early, none of the potential
benefits mentioned in this section have been clearly demonstrated
in controlled trials. Several comments noted that cognitive impair-
ment often goes unrecognized. The USPSTF agrees and added
language to the Practice Considerations section noting that clini-
cians should remain alert to early signs or symptoms of cognitive im-
pairment. Some comments suggested additional studies that
should be considered by the USPSTF. Some of the suggested stud-
ies investigated the prevention of cognitive impairment by control-
ling risk factors, such as hypertension, or by use of a multidomain
intervention (eg, diet, physical activity, cognitive training, and risk
factor control). However, none of these suggested studies met in-
clusion criteria for this recommendation; that is, they were not stud-
ies of screening for and/or treatment of cognitive impairment or mild
to moderate dementia. Also, the USPSTF added the American Acad-
emy of Neurology’s guidelines on the detection of cognitive impair-
ment to the Recommendations of Others section.
How Does Evidence Fit With Biological Understanding?
Dementia can be the result of varied and different pathophysi-
ologic processes affecting the brain, and the exact causal mecha-
nism for many types of dementia is unknown. Therefore, the devel-
opment of early interventions that result in important clinical effects
on dementia has been challenging. The most common cause of de-
mentia in the United States is Alzheimer disease, which is the tar-
get of all current drugs approved by the US Food and Drug Admin-
istration for dementia. Since current medical therapies for dementia
do not appear to affect its long-term course, the potential benefit
of screening may be in devising effective interventions that can help
patients and caregivers prepare for managing the symptoms and con-
sequences of dementia.
Research Needs and Gaps
• More research is needed on the effect of screening and early
detection of cognitive impairment (MCI and mild to moderate
dementia) on important patient, caregiver, and societal out-
comes, including decision-making, advance planning, and care-
giver outcomes.
• The body of evidence on screening and interventions for cogni-
tive impairment would benefit from more consistent definitions
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and reporting of outcomes to allow comparisons across trials,
especially from trials with longer-term follow-up.
• Studies are needed of the effects of caregiver or patient-
caregiver dyad interventions on delay or prevention of institu-
tionalization, and the effects of delay in institutionalization
on caregivers.
• Research is needed on treatments that clearly affect the long-
term clinical course of cognitive impairment. It is also important
that studies on screening and interventions for cognitive impair-
ment report harms and reasons for attrition of trial participants.
Recommendations of Others
The American Academy of Family Physicians supports the 2014
USPSTF recommendation on screening for cognitive impair-
ment in older adults.41 The American Academy of Neurology
has published guidance on the detection of cognitive impairment
during the annual wellness visit and recommends the use of a
brief, validated cognitive assessment instrument to assess for
cognitive impairment.42
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